Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
BMJ open（2023）
摘要
ClinicalTrials.gov Identifier: NCT04823247 (Pre-results).
更多查看译文
关键词
epidemiology,psoriasis,therapeutics
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要